Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — FY2023 Earnings Presentation
28 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, Apr 8, 2024
Slide 1: 2023 Annual Results Presentation
2023 Annual Results Presentation April 2024
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the
Slide 3: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 3
Slide 4: 2023 Key Take Away
2023 Key Take Away Robust Revenue Growth Significant Decrease of Revenue 384%YOY Net Free Cash Outflow 42% YOY #1 Market Share 8 Regulatory Approvals among domestic brands accelerated conversion of R&D outcomes New Globalization Milestone 5G Remote Surgeries 1st overseas order of Toumai ® Toumai ® 1
Slide 5: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 5
Slide 6: Ramped-up domestic sales orders driven by ambitious pursuit of market share
Business Highlights Ramped-up domestic sales orders driven by ambitious pursuit of market share Core Product Toumai ® Other Flagship Products Gaining meaningful market share for long • 3 wining bids with 3 installed to date Robust sales growth upon the NMPA approval for multidisciplinary application
Slide 7: Significant strides in globalization with overseas orders secured by Toumai
Business Highlights Significant strides in globalization with the 1st and more overseas orders secured by Toumai ® Cross Border Opportunities Our Global Footprint A new record in overseas commercialization: • Toumai® successfully sealed its 1st overseas orders with SkyWalkerTM more potential orders
Slide 8: Commercialization: comprehensive product offering across 5 surgical specialties
Business Highlights Comprehensive product offering covering all 5 major and fast-growing surgical specialties Laparoscopic Orthopedic Panvascular Percutaneous Natural Orifice Offering Product Toumai® DFVision ® Skywalker TM R-ONE® Mona Lisa Trans-bronchial Surgical Robot NMPA （TKA） NMPA Achievements
Slide 9: Continuous efforts in executing a proven strategy
Business Highlights Continuous efforts in executing a proven strategy Dedicated Market Rapid Increase of Comprehensive For complicated Cultivation Clinical Validation Coverage Disease Toumai® Toumai® Toumai® Toumai® 35 2,000+ First of its kind completed with a Chinese- Training Centers 31 90+ develo
Slide 10: Benchmark for integration of 5G technology and surgical robot
Business Highlights Establishing a benchmark for integration of 5G technology and surgical robot The world's first transcontinental 5G remote surgery verification Xinjiang Beijing Orlando 5,000 km 12,500+ km 12,950+ km Shanghai Shanghai Dubai Sanya The world’s only 120+ remote surgery clinical trial
Slide 11: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 11
Slide 12: Comprehensive product offering covering major surgical specialties
Product Pipeline Update Comprehensive product offering covering all 5 major and fast-growing surgical specialties Medical Device Surgical Indicated Product Clinical Trial/ Specialty Product Application Classification Design Development Design Validation Clinical Evaluation Registration Application T
Slide 13: Flagship product – Toumai Laparoscopic Surgical Robot
Product Pipeline Update Flagship product– Toumai® Laparoscopic Surgical Robot Multiple generations of Domestic registration Toumai® clinical progress • Toumai ® 2nd obtained NMPA approval in Oct. 2023 Commercialization 2018 Completed the design for Toumai® 1st Generation • maintained leading positio
Slide 14: Flagship product – SkyWalker Orthopedic Surgical Robot
Product Pipeline Update Flagship product – SkyWalkerTM Orthopedic Surgical Robot The 1st domestic surgical robot to expand into global market Apr 2022 Jul 2022 Apr 2023 Jul 2023 Feb 2024 Sep 2023 NMPA FDA Dec 2022 NMPA ANVISA TGA UKCA Approval Clearance CE Marking Approval Approval Approval Approval
Slide 15: Flagship product – DFVision 3D Electronic Laparoscope
Product Pipeline Update Flagship product – DFVision® 3D Electronic Laparoscope Underlying technology to Steady commercialization – Decent sales in FY2023 contimuously optimize the high-end pioneer among domestic brands vision platform for surgical robots Stereo visualization The natural depth of fie
Slide 16: Natural Orifice Surgical Robot
Product Pipeline Update Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Product Surgery application Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human bod
Slide 17: R-ONE Vascular Interventional Robot System
Product Pipeline Update R-ONE® Vascular Interventional Robot System Designed to operate with precision and NMPA approval perform specific movements CE mark Facilitate and enhance the interventional procedures performed on the patient Registration Approval Strong Commercialization Unique Synergy & Le
Slide 18: Mona Lisa Robotic Transperineal Prostate Biopsy System
Product Pipeline Update Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA Approval Real-time ultrasound images displayed on the monitor FDA Approval during the biopsy procedure CE Marking TGA Approval The surgeon manually inserts the needle into the prostate to collect the biopsy cores HAS
Slide 19: Strong industrial operation capabilities for surgical robots
Product Pipeline Update Strong industrial operation capabilities for surgical robots 1,278 Multilayered supply chain system applications In-house designed components (1145 invention patents) 365 Scalable production of Toumai®, overseas applications SkyWalkerTM and consumables (132 granted) Annual ca
Slide 20: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 20
Slide 21: Consolidated Financial Performance
Financial Review Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH FLOW Total revenue reached 104.6m with 384% growth. Core It turned to decrease with the strategy shaping, e.g. focus on The success of costs reduction and operation efficiency led product Toumai® obtained NMPA appro
Slide 22: Operating Expenses
Financial Review Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) (RMB million) (RMB million) 25% 30% 26% 93% 59% 132% 755.8 238.4 170.5 569.2 184.0 126.4 392.6 107.5 79.2 2021 2022 2023 2021 2022 2023 2021 2022 2023 R&D 569.2m, 25% decline YoY S&M 238.4m, grew by 30% Y
Slide 23: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 23
Slide 24: In Closing
In Closing We delivered record revenue and robust momentum to drive continuous growth We enjoy large, cross-border market opportunities Our comprehensive product pipeline enables technology integration, stimulates sales synergy, and provides integrated diagnostic and treatment solutions We are posit
Slide 25: Agenda
AGENDA 2023 Key Take Away Business Highlights Product Pipeline Update Financial Review In Closing Appendix 25
Slide 26: Appendix I - Consolidated Balance Sheet
Appendix I - Consolidated Balance Sheet Unit: RMB'000 31 Dec 2023 31 Dec 2022 Var. Unit: RMB'000 31 Dec 2023 31 Dec 2022 Var. Non-current assets CAPITAL AND RESERVES Share capital 958,594 958,594 0% Property, plant and equipment 367,017 491,576 -25% Intangible assets 9,537 7,053 35% Reserves (439,11
Slide 27: Appendix II - Consolidated P&L
Appendix II - Consolidated P&L Unit: RMB'000 2023 2022 Var. Revenue 104,592 21,603 384% Cost of sales (89,898) (15,041) 498% Gross profit 14,694 6,562 124% Other net income (13,342) 42,078 -132% Selling and marketing expenses (238,428) (184,042) 30% Administrative expenses (126,361) (170,472) -26% R
Slide 28: Thank You
ey MEUBOT PX GUANES A THANK YOU Basa) Gear]
Shanghai MicroPort MedBot (Group) — FY2023 Earnings Presentation on 6ix